oxLDL specifically impairs endothelium-dependent, NO-mediated dilation of coronary arterioles

被引:81
作者
Hein, TW
Liao, JC
Kuo, L [1 ]
机构
[1] Texas A&M Univ, Cardiovasc Res Unit, Dept Med Physiol, Syst Hlth Sci Ctr, College Stn, TX 77843 USA
[2] Univ Calif Los Angeles, Dept Chem Engn, Los Angeles, CA 90095 USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY | 2000年 / 278卷 / 01期
关键词
atherosclerosis; nitric oxide; potassium channels;
D O I
10.1152/ajpheart.2000.278.1.H175
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Our previous studies implicated thatoxidized low-density lipoprotein (oxLDL), a putative atherogenic agent, impairs endothelium-dependent, nitric Oxide (NO)-mediated dilation of isolated coronary arterioles to-pharmacological agonists. However, it is not known whether oxLDL specifically affects NO-mediated dilation-or: generally impairs endothelium-dependent function, including the release of hyperpolarizing factors. In this regard, we investigated the dilation of isolated porcine coronary arterioles (50- to 100-mu m luminal diameter) in response to the activation of various endothelium-dependent pathways before and after intraluminal incubation of the vessels with oxLDL (0.5 mg: protein/ml for 60 min). In the absence of oxLDL, all vessels developed basal tone and dilated in response to the activation of NO synthase (by flow and adenosine), :cyclooxygenase (by arachidonic acid), cytochrome P-450 monooxygenase (by bradykinin), and endothelial membrane hyperpolarization (by sucrose-induced hyperosmolarity). Incubation of the vessels with oxLDL for 60 min did not alter basal tone but did inhibit the vasodilatory responses to increased flow and adenosine in a manner similar to that of the NO synthase inhibitor NG-nitro-L-arginine methyl ester. Vasodilations in response to flow and adenosine were not affected by intraluminal incubation of the vessels with either a vehicle solution or the native LDL (0.5 mg protein/ml, 60 min). In contrast with the NO-mediated response, hyperosmotic vasodilation mediated by endothelial hyperpolarization was not affected:by oxLDL. Endothelium-dependent dilations to the cyclooxygenase activator arachidonic acid and to the cytochrome P-450 monooxygenase activator bradykinin and endothelium-independent vasodilation to sodium nitroprusside were also not altered by oxLDL. Collectively, these results;indicate that oxLDL has a selective effect on endothelium-dependent dilation with specific impairment of the NO-mediated :response, whereas cyclooxygenase and cytochrome P-450 monooxygenase-mediated dilations are spared from this inhibitory effect. In addition, oxLDL does not appear to:affect vasodilation mediated by hyperpolarization of the endothelium.
引用
收藏
页码:H175 / H183
页数:9
相关论文
共 60 条
[1]  
Abebe W, 1997, J PHARMACOL EXP THER, V282, P851
[2]   PLASMA-PROTEIN CONCENTRATION AND CONTROL OF CORONARY VASCULAR-RESISTANCE IN ISOLATED RAT-HEART [J].
AVOLIO, AP ;
SPAAN, JAE ;
LAIRD, JD .
AMERICAN JOURNAL OF PHYSIOLOGY, 1980, 238 (04) :H471-H480
[3]   THE ROLE OF ADENOSINE IN THE REGULATION OF CORONARY BLOOD-FLOW [J].
BERNE, RM .
CIRCULATION RESEARCH, 1980, 47 (06) :807-813
[4]  
BOGER RH, 1995, ATHEROSCLEROSIS, V117, P273, DOI 10.1016/0021-9150(95)05582-H
[5]  
Chait A, 1992, CURR OPIN LIPIDOL, V3, P389
[6]   EFFECTS OF ATHEROSCLEROSIS ON THE CORONARY MICROCIRCULATION [J].
CHILIAN, WM ;
DELLSPERGER, KC ;
LAYNE, SM ;
EASTHAM, CL ;
ARMSTRONG, MA ;
MARCUS, ML ;
HEISTAD, DD .
AMERICAN JOURNAL OF PHYSIOLOGY, 1990, 258 (02) :H529-H539
[7]   MICROVASCULAR DISTRIBUTION OF CORONARY VASCULAR-RESISTANCE IN BEATING LEFT-VENTRICLE [J].
CHILIAN, WM ;
EASTHAM, CL ;
MARCUS, ML .
AMERICAN JOURNAL OF PHYSIOLOGY, 1986, 251 (04) :H779-H788
[8]   INACTIVATION OF ENDOTHELIAL DERIVED RELAXING FACTOR BY OXIDIZED LIPOPROTEINS [J].
CHIN, JH ;
AZHAR, S ;
HOFFMAN, BB .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 89 (01) :10-18
[9]   ATHEROSCLEROSIS IMPAIRS FLOW-MEDIATED DILATION OF CORONARY-ARTERIES IN HUMANS [J].
COX, DA ;
VITA, JA ;
TREASURE, CB ;
FISH, RD ;
ALEXANDER, RW ;
GANZ, P ;
SELWYN, AP .
CIRCULATION, 1989, 80 (03) :458-465
[10]  
Cox DA, 1996, PHARMACOL REV, V48, P3